Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals' stock price has significantly declined over the past year. In December 2025, the company reported fiscal year 2025 financial results, highlighting the commercial launch of LYMPHIR, and Citius Oncology announced an $18 million concurrent registered direct offering and private placement. In July 2025, news of a distribution deal with Cencora boosted Citius shares. In June 2025, Citius Pharmaceuticals regained Nasdaq compliance and Citius Oncology entered into a distribution services agreement with Cardinal Health. In May 2025, Citius Pharmaceuticals reported GAAP EPS of -$0.11, beating estimates. In April 2025, the stock tumbled to a 52-week low. In August 2024, the FDA approved LYMPHIR.

Information directly detailing demand seasonality for Citius Pharmaceuticals' specific products and services was not found. The demand for critical care products is generally driven by medical necessity and disease prevalence rather than typical seasonal consumer patterns. Seasonal patterns were noted for CTXR's option volatility, with implied volatility tending to rise most in July and decline to its lowest levels in March, but this reflects market trading behavior rather than product demand.

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing critical care products, operating in the Biotechnology and Pharmaceutical industries. The company focuses on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. Its major products and pipeline candidates include LYMPHIR™ for cutaneous T-cell lymphoma, Mino-Lok® for catheter-related bloodstream infections, Halo-Lido for hemorrhoids, and NoveCite for Acute Respiratory Distress Syndrome.

Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey, United States. The company intends to enhance its international presence, with LYMPHIR expected to reach 19 non-U.S. markets through an exclusive distribution agreement.

Citius Pharmaceuticals' brand reputation has been influenced by the FDA approval and commercial launch of LYMPHIR, but also by challenges in commercialization, concerns about liquidity, and a significant decline in stock price. The consensus analyst rating for CTXR is "Hold."

Citius Pharmaceuticals is primarily owned by retail investors, with institutional shareholders and insiders holding smaller percentages. Major institutional owners include Vanguard Group Inc, Geode Capital Management, Llc, and BlackRock, Inc. The largest individual shareholder is Leonard L. Mazur.